• FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

1234
Who We Are:

Learn about our commitment to FGFR-driven diseases

Our Product:

Discover the role of FGFR inhibition

Achondroplasia:

Learn about PROPEL and PROPEL 2

Latest Press Releases

05.28.2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

03.31.2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration To Co-Develop and Commercialize Infigratinib in Oncology

12.01.2020

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

Contact Us

8000 Marina Blvd, Suite 400, Brisbane, CA 94005

1-877-280-5655

For additional information, reach out to info@qedtx.com

Maps were disabled by the visitor on this site.